Research programme: hypersensitivity LAMP vaccines - Immunomic Therapeutics

Drug Profile

Research programme: hypersensitivity LAMP vaccines - Immunomic Therapeutics

Alternative Names: Multi allergen vaccine - Immunomic; MULTI-LAMP-vax

Latest Information Update: 07 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunomic Therapeutics
  • Developer Astellas Pharma; Immunomic Therapeutics
  • Class DNA vaccines; Food allergy immunotherapies
  • Mechanism of Action Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypersensitivity

Most Recent Events

  • 03 Mar 2017 Preclinical trials in Hypersensitivity (Prevention) in USA (unspecified route)
  • 22 Dec 2016 Preclinical trials in Hypersensitivity in USA (unspecified route) (Immunomic Pipeline, December 2016)
  • 22 Nov 2016 Immunomic Therapeutics has patent protection for LAMP-Vax™ technology in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top